Trial Profile
A Phase 1 Study of Amrubicin in Combination With Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 May 2018 Status changed from active, no longer recruiting to completed.
- 11 Jan 2017 protocol was amended to update the primary endpoint and its time frame.
- 11 Jan 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.